Is Bajaj Healthcare Overvalued or Undervalued Right Now?
- August 31, 2026
- Posted by: Kunal Singla
- Category: Market
Bajaj Healthcare CMP Rs 329.95 (31 Aug 2026), up 2.47%. PE 61.47 vs industry PE 51.43. ROE 8.81%. 52W range Rs 272.35 to Rs 515.90.
Quick Answer
Bajaj Healthcare trades at a price to earnings ratio of 61.47 against an industry average of 51.43, which puts the stock close to fair value on a simple multiple basis rather than clearly overvalued or undervalued. The company’s 8.81% return on equity and Rs 158.34 book value per share fit broadly within its sector’s range. Whether Bajaj Healthcare is overvalued or undervalued right now is less about a wide valuation gap and more about how its growth and margins evolve from here.
Is Bajaj Healthcare overvalued or undervalued right now is a question worth asking given how its price to earnings ratio compares with the rest of its sector. At the current market price of Rs 329.95, the stock trades roughly 36.0% below its 52 week high of Rs 515.90 and about 21.1% above its 52 week low of Rs 272.35.
Bajaj Healthcare’s share price moved up 2.47% in Monday’s session to Rs 329.95, against a market capitalisation of Rs 1,084 Cr. This article looks at the numbers, the PE ratio, price to book, return on equity, debt levels and recent earnings trends, that determine whether the current price reflects fair value or a stretched multiple.
Click Here – Get Free Investment Predictions
Bajaj Healthcare Valuation Metrics: Where Does the Stock Stand?
| Valuation Metric | Bajaj Healthcare |
|---|---|
| CMP (31 Aug 2026) | Rs 329.95 |
| Market Cap | Rs 1,084 Cr |
| P/E Ratio | 61.47 |
| Industry P/E | 51.43 |
| P/B Ratio | 2.03 |
| Sector Average P/B (pharmaceutical) | 7.31 |
| Return on Equity (ROE) | 8.81% |
| Sector Average ROE (pharmaceutical) | 12.94% |
| EPS (TTM) | Rs 5.24 |
| Book Value per Share | Rs 158.34 |
| Debt to Equity | 0.47 |
| Dividend Yield | 0.47% |
| Sector Average Dividend Yield (pharmaceutical) | 0.30% |
| 52 Week High / Low | Rs 515.90 / Rs 272.35 |
The headline number here is the price to earnings ratio. At 61.47, the Bajaj Healthcare PE ratio is 1.2 times the industry average of 51.43. Measured against its pharmaceutical sector peers, the gap widens further on other measures too: a P/B of 2.03 against a sector average of 7.31, and an ROE of 8.81% against a sector average of 12.94%.
Is Bajaj Healthcare Overvalued Based on Its P/E Ratio?
Based on the P/E ratio alone, Bajaj Healthcare looks fairly valued. The stock’s PE of 61.47 sits close to the industry average of 51.43, which suggests the market is pricing the business roughly in line with its sector rather than at a premium or a discount. That leaves the read on whether Bajaj Healthcare is overvalued or undervalued more dependent on its growth trajectory than on the PE ratio itself.
Check Bajaj Healthcare’s Live Fundamentals on the Univest Screener
Bajaj Healthcare’s Financial Growth and Profitability
Detailed multi-year revenue and profit figures were not available for Bajaj Healthcare at the time of writing, so this section relies on the metrics that are confirmed: a return on equity of 8.81%, an EPS of Rs 5.24, and a book value of Rs 158.34 per share. Readers should treat the valuation call here as based on current ratios rather than a multi-year earnings trend.
Download the Univest iOS App or Univest Android App to track Bajaj Healthcare’s live share price and valuation ratios.
Arguments That Bajaj Healthcare Could Be Overvalued
- Low dividend yield: At 0.47%, the stock offers little income cushion if the growth story slows.
- Limited margin of safety: At Rs 329.95, the stock is only 36.0% below its 52 week high of Rs 515.90, leaving less room for error if earnings disappoint.
Arguments That Support the Premium Valuation
- Low leverage: A debt to equity ratio of 0.47 gives Bajaj Healthcare a comparatively strong balance sheet.
- 52 week range context: At Rs 329.95, the stock is 21.1% above its 52 week low of Rs 272.35, showing it has already found some support at lower levels.
Verdict: Is Bajaj Healthcare Overvalued or Undervalued Right Now?
On balance, Bajaj Healthcare looks fairly valued rather than clearly overvalued or undervalued. Its PE of 61.47 sits close to the industry average of 51.43, and its 8.81% ROE and other ratios do not point to a significant mispricing either way. The more useful question for investors from here is less about the current multiple and more about whether earnings growth accelerates or slows.
What Could Change This Valuation Picture for Bajaj Healthcare?
Two broad scenarios could shift this valuation call on Bajaj Healthcare in either direction. On the upside, an improvement in return ratios or growth that pushes the stock’s PE of 61.47 toward a premium over the industry average of 51.43. On the downside, a deterioration in the numbers that pulls the PE below the industry average of 51.43 instead. Investors watching the Bajaj Healthcare share price over the next few quarters should track whether reported ROE holds near 8.81% and whether the PE gap versus the industry average of 51.43 widens or narrows, since both will matter more to the eventual answer than the current price point on its own.
Conclusion
Bajaj Healthcare’s numbers point to a stock that is fairly valued on headline multiples. Investors tracking the Bajaj Healthcare share price should watch whether earnings growth can keep pace with the current PE of 61.47, since that gap remains the single biggest variable in whether the stock is undervalued, fairly priced, or overvalued from here. This article is for informational purposes only and is not investment advice.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Bajaj Healthcare Valuation
Is Bajaj Healthcare overvalued or undervalued right now?
Ans. Based on a PE ratio of 61.47 against an industry average of 51.43, Bajaj Healthcare currently looks fairly valued on relative valuation. Its 8.81% ROE is an important part of the picture alongside the PE ratio.
What is Bajaj Healthcare’s current PE ratio?
Ans. Bajaj Healthcare’s price to earnings ratio stands at 61.47, compared with an industry average PE of 51.43.
What is Bajaj Healthcare’s return on equity?
Ans. Bajaj Healthcare generates a return on equity of 8.81%, against a sector average of 12.94% among pharmaceutical peers.
What is Bajaj Healthcare’s 52 week high and low?
Ans. Bajaj Healthcare’s 52 week high is Rs 515.90 and its 52 week low is Rs 272.35. The stock currently trades around Rs 329.95, roughly 36.0% below its high.
Does Bajaj Healthcare have high debt?
Ans. Bajaj Healthcare carries a debt to equity ratio of 0.47, which is low for its sector.
What is Bajaj Healthcare’s dividend yield?
Ans. Bajaj Healthcare offers a dividend yield of 0.47% at the current share price.
Is Bajaj Healthcare a good stock to buy at current levels?
Ans. Bajaj Healthcare’s current valuation suits investors who agree with the fairly valued read on its PE ratio and are comfortable with the trade-off between its return ratios and its price. This is for informational purposes only and is not investment advice.
What is Bajaj Healthcare’s price to book ratio?
Ans. Bajaj Healthcare trades at a price to book ratio of 2.03, compared with a sector average of 7.31 among pharmaceutical peers.
